MT 8 - MimeTech/ Recordati

Drug Profile

MT 8 - MimeTech/ Recordati

Alternative Names: MT-8; Negermin methyl ester

Latest Information Update: 10 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Universita degli Studi di Firenze
  • Developer MimeTech; Recordati
  • Class Cardiovascular therapies; Eye disorder therapies; Nerve growth factors; Neuroprotectants; Skin disorder therapies
  • Mechanism of Action Apoptosis inhibitors; Nerve growth factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Keratitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Keratitis
  • Preclinical Dry eyes; Glaucoma; Myocardial infarction; Pressure ulcer; Retinitis pigmentosa; Sickle cell anaemia

Most Recent Events

  • 16 Jun 2017 Recordati in-licenses MT 8 for Neurotrophic keratitis from MimeTech
  • 16 Jun 2017 Phase-I clinical trials in Keratitis in Italy (unspecified route)
  • 16 Jun 2017 Preclinical trials in Dry eyes in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top